Evidence map›Paper›PMID 18226221›Full record

ArticleBMC cell biology2008

Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors.

Jolyon Terragni, Julie R Graham, Kenneth W Adams, Michael E Schaffer, John W Tullai, Geoffrey M Cooper

Open access · goldAbstract read
In one paragraph

Article in BMC cell biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. L-Carnitine Attenuates Cardiac Dysfunction by Ischemic Insults Through Akt Signaling Pathway.Toxicological sciences : an official journal of the Society of Toxicology · 2017
    Article
  7. Article
  8. Article
  9. Article
  10. Reengineered tricyclic anti-cancer agents.Bioorganic & medicinal chemistry · 2015
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jolyon TerragniDepartment of Biology, Boston University, Boston MA 02215, USA. jolyon@bu.edu
Julie R Graham
Kenneth W Adams
Michael E Schaffer
John W Tullai
Geoffrey M Cooper
Boston University · USUniversity of Massachusetts Boston · USPfizer (United States) · US

Funding

Regulation of apoptosis by PI 3-kinase/Akt signalingR01CA018689 · NCI · DANA-FARBER CANCER INSTITUTE · PI COOPER, GEOFFREY M · 1985 to 2012
$6.2M
NCI NIH HHS R01 CA018689NCI NIH HHS R01 CA18689
6 · The paper itself

Abstract

backgroundPhosphatidylinositol (PI) 3-kinase is activated by a variety of growth factor receptors and the PI 3-kinase/Akt signaling pathway is a key regulator of cell proliferation and survival. The downstream targets of PI 3-kinase/Akt signaling include direct regulators of cell cycle progression and apoptosis as well as a number of transcription factors. Growth factor stimulation of quiescent cells leads to robust activation of PI 3-kinase, induction of immediate-early genes, and re-entry into the cell cycle. A lower level of PI 3-kinase signaling is also required for the proliferation and survival of cells maintained in the presence of growth factors, but the gene expression program controlled by PI 3-kinase signaling in proliferating cells has not been elucidated.

resultsWe used microarray analyses to characterize the changes in gene expression resulting from inhibition of PI 3-kinase in proliferating cells. The genes regulated by inhibition of PI 3-kinase in proliferating cells were distinct from genes induced by growth factor stimulation of quiescent cells and highly enriched in genes that regulate programmed cell death. Computational analyses followed by chromatin immunoprecipitations demonstrated FOXO binding to both previously known and novel sites in promoter regions of approximately one-third of the up-regulated genes, consistent with activation of FOXO1 and FOXO3a in response to inhibition of PI 3-kinase. NFkappaB binding sites were similarly identified in promoter regions of over one-third of the down-regulated genes. RelB was constitutively bound to promoter regions in cells maintained in serum, however binding decreased following PI 3-kinase inhibition, indicating that PI 3-kinase signaling activates NFkappaB via the non-canonical pathway in proliferating cells. Approximately 70% of the genes targeted by FOXO and NFkappaB regulate cell proliferation and apoptosis, including several regulators of apoptosis that were not previously known to be targeted by these transcription factors.

conclusionPI 3-kinase signaling in proliferating cells regulates a novel transcriptional program that is highly enriched in genes that regulate apoptosis. At least one-third of these genes are regulated either by FOXO transcription factors, which are activated following PI 3-kinase inhibition, or by RelB, which is activated by PI 3-kinase via the non-canonical pathway in proliferating cells.

Indexed as

Cell ProliferationTranscription, GeneticApoptosisBinding SitesChromonesForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMorpholinesNF-kappa BOligonucleotide Array Sequence AnalysisPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein BindingSignal Transduction2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneChromonesForkhead Transcription FactorsMorpholinesNF-kappa BPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsTranscription Factors

Identifiers

PMID18226221
PMCPMC2268685
OpenAlexW2164558299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.